Ye Xu: Clinical Trials

2 trials sponsored by Ye Xu, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 not yet recruiting, 1 unknown. 1 Phase 2, 1 Phase 3, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 21Unknown 1
Phase 31Unknown 1
Phase 41Not yet recruiting 1

Follow Ye Xu: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer
Serplulimab, Fruquintinib, mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU) - Colorectal Cancer (Locally Advanced or Metastatic), Colorectal Cancer Microsatellite Stable (MSS)
Phase 4Not yet recruitingYe Xu422026-03-012026-03-03
Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer
Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6), Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6) - Resected Liver Metastases From Colorectal Cancer
Phase 2 / Phase 3UnknownYe Xu4322015-09-012015-08-20

Conditions studied

Colorectal Neoplasms (1)  ·  Neoplasm Metastasis (1)

Interventions

Fluorouracil (2)  ·  Leucovorin (2)  ·  Oxaliplatin (2)  ·  Capecitabine (1)  ·  Floxuridine (1)  ·  HMPL-013 (1)  ·  Heparin (1)

Countries

China (2)